查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992614

脉络膜新生血管市场：2026-2032年全球市场预测（依治疗方法、药物类别、疾病类型、病变类型、治疗阶段、通路和最终用户划分）

Choroidal Neovascularization Market by Treatment Type, Drug Class, Disease Type, Lesion Type, Line Of Therapy, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，脉络膜新生血管市场价值将达到 68.8 亿美元，到 2026 年将成长至 73.6 亿美元，到 2032 年将达到 116.9 亿美元，复合年增长率为 7.86%。

主要市场统计数据
基准年 2025 68.8亿美元
预计年份：2026年 73.6亿美元
预测年份：2032年 116.9亿美元
复合年增长率 (%) 7.86%

这是一篇清晰而全面的脉络膜新生血管介绍，概述了其临床特征、诊断方法的进展以及不断发展的治疗前景。

脉络膜新生血管（CNV）是影响脉络膜-视网膜交界处最严重的併发症之一，可导致视力丧失、长期併发症，并影响医疗资源的分配。本文概述了CNV的临床特征、诊断途径和目前治疗标准，这些因素共同塑造了CNV的治疗和商业性格局。多模态影像和早期检测技术的进步显着改善了患者的预后，使得更及时的干预成为可能，从而改变了疾病的进展和患者的结果。然而，这些诊断技术的进步也增加了眼科医师、视网膜专家和门诊手术中心之间协调诊疗工作的复杂性。

重塑 CNV 治疗的范式和相关人员的期望：从跨学科的观点转变科学、临床和交付模式。

目前，脉络膜新生血管（CNV）的治疗正经历着一场变革，这主要得益于科学创新、医疗服务模式的演变以及对以患者为中心的治疗结果的重新关注。抗血管内皮生长因子（VEGF）药物的生物学和分子工程改进延长了其作用持续时间并改善了其安全性，促使临床医生重新评估给药间隔和随访方案。同时，来自真实世界数据和註册登记的见解正在帮助优化治疗方法，尤其是在病变形态复杂或对一线治疗反应不佳的患者中。这些临床趋势与营运方式的改变交织在一起。虽然门诊手术中心和眼科诊所的设备越来越完善，能够提供复杂的玻璃体内注射治疗，但对于更严重的病例，医院系统仍然发挥核心作用。

对 2025 年美国关税环境将如何重塑 CNV 治疗的供应链韧性、製造地和商业合约进行策略分析。

2025年美国关税调整的累积影响正在改变脉络膜新生血管（CNV）治疗及相关医疗设备的成本结构和供应链动态。进口生技药品成分、包装材料和专用给药装置的关税调整增加了部分製造商的采购成本，迫使他们重新评估筹资策略。因此，一些公司正在加快生技药品生产关键流程的在地化进程，并实现供应商多元化，涵盖多个地区，以降低贸易政策波动带来的风险。此类供应链重组可能导致前置作业时间延长和短期库存失衡，因此需要积极主动地进行库存和分销规划。

将治疗方法、分子分类、病变和疾病表型、医疗保健环境和分销管道与可操作的临床和商业策略联繫起来的详细細項分析。

細項分析揭示了治疗方法方案、分子分型、临床症状、病变特征、治疗线、分销管道和终端用户类型如何相互交织，共同塑造需求趋势和治疗管道。治疗方法类型仍然是一个主要因素。抗VEGF疗法在治疗决策中占据主导地位，阿维西普和雷珠单抗等药物之间的分子水平差异会影响给药间隔和患者追踪。在某些医疗机构中，Bevacizumab因其成本效益而仍然重要，而具有改良分子结构的新型入门级药物旨在延长疗效持续时间并提高安全性。动态疗法和抗VEGF药物的联合疗法被选择性地用于某些难治性或非典型病变，而基于维替泊芬的动态在某些病变亚型中仍然发挥作用。

关于 CNV，它是一种区域策略展望，旨在协调全球主要医疗保健区域内临床实践的多样性、监管差异和供应链现实。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的临床实践、监管管道和商业模式均产生显着影响。在美洲，先进的视网膜医疗基础设施和积极的都市区创新正在塑造市场发展，但支付方的复杂性和报销政策的差异导致准入管道不均，因此需要製定个性化的打入市场策略。相较之下，欧洲、中东和非洲的管理体制和医疗保健财务模式各不相同，一些市场正在快速接受先进的生技药品，而其他市场则受到预算上限的限制。应对这些差异需要细緻的沟通和证据生成，并根据具体国家情况进行调整，以支持报销申请。亚太地区呈现出复杂的格局，庞大的病患群体和不断增长的专科医生数量与采购方式、价格敏感度和监管时间表的差异并存。在地化生产和区域伙伴关係对于商业性成功至关重要。

企业级竞争对手强调分子层级创新、真实世界证据、病患支持和供应链韧性，以此作为 CNV 差异化的基础。

企业层面的关键趋势集中在分子设计、生命週期管理和患者支援基础设施的创新。研发人员正致力于开发新一代抗VEGF药物，以延长保存期限、优化安全性，并透过独特的作用机制和剂型实现差异化。策略重点包括建立强大的真实世界数据专案以验证疗效对比，建立全面的患者支援和用药依从性服务，以及投资于生产冗余以降低供应风险。随着各公司努力简化产品获取流程并克服处理复杂生技药品相关的物流挑战，创新製药公司与专业分销商和医院系统之间的伙伴关係变得日益重要。

行业领导者利用可操作和优先考虑的建议，来协调证据生成、製造韧性、准入计划和支付方合作，从而实现 CNV 的成功。

为了将本报告的洞见转化为实际营运优势，产业领导者应优先考虑一系列切实可行的倡议，使临床差异化与商业性可行性相契合。首先，应将实证研究工作重点放在直接比较试验和真实世界比较研究上，以明确不同病变亚型和治疗方案的治疗定位。这些证据将有助于加强与支付方的沟通，并提升临床医师的信心。其次，应投资建立灵活的生产系统以及区域填充和包装能力，以减轻关税中断对供应链的影响，并缩短关键物资的前置作业时间。第三，应根据不同的分销管道和终端用户的实际情况，量身定制准入和患者支持计划，确保门诊手术中心和眼科诊所获得后勤和教育支持，从而优化患者的用药依从性和治疗效果。

采用严谨的混合调查方法，结合关键相关人员的访谈和系统的二手文献综述，并辅以可靠的检验和品管。

本分析的调查方法整合了第一手和第二手调查，以确保其可靠性、有效性和可操作性。第一手调查包括对视网膜专家、医院药剂师、诊所管理人员和保险公司代表进行半结构式访谈，以收集他们对治疗决策、营运限制和就医挑战的直接看法。第二手调查包括对同行评审的临床文献、监管申报文件、临床实验室註册数据以及专业学会发布的公开指南进行系统性回顾，以确定治疗模式和特异性病变的治疗结果。数据三角检验将定性研究结果与已发表的临床证据相结合，以检验新出现的主题并识别临床实验室人群与临床实践之间的差异。

要将慢性非兽医疾病 (CNV) 治疗的进步转化为可持续的患者疗效和商业性成功，必须将临床创新、营运韧性和保险公司合作策略进行明确的整合。

总之，CNV（血管内皮生长因子）是一个科学和商业性都快速发展的领域，患者能否获得治疗以及治疗效果取决于临床创新、供应链策略和支付方合作的综合作用。抗VEGF生物学和辅助性治疗的进步使得更个人化的治疗模式成为可能，但这些机会必须辅以实证医学证据的累积、生产能力的提升以及对目标市场准入计画的投入。价格趋势和区域监管的复杂性进一步增加了商业风险，但企业可以透过采购多元化、区域伙伴关係和积极的支付方策略来降低这些风险。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 脉络膜新生血管市场：依治疗方法

  • 抗 VEGF 疗法
    • 阿柏西普
    • Bevacizumab
    • 布罗卢西珠单抗
    • 康维赛特
    • 雷尼珠单抗
  • 联合治疗
  • 动态疗法

第九章：脉络膜新生血管市场：依药物类别划分

  • 融合蛋白
  • 单株抗体

第十章 脉络膜新生血管市场：依疾病类型划分

  • 新生血管性老年黄斑部病变老龄化
  • 病理性近视

第十一章：脉络膜新生血管市场：依病变类型划分

  • 典型拷贝数变异
  • 混合拷贝数变异
  • 潜在拷贝数变异

第十二章 脉络膜新生血管市场：依治疗阶段划分

  • 第 1 行
  • 第二行
  • 第三行

第十三章：脉络膜新生血管市场：依通路划分

  • 在线的
  • 离线

第十四章 脉络膜新生血管市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 眼科诊所

第十五章 脉络膜新生血管市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 脉络膜新生血管市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 脉络膜新生血管市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国脉络膜新生血管市场

第十九章：中国脉络膜新生血管市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Adverum BIoTechnologies
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bausch+Lomb Corporation
  • Bausch Health
  • Bayer AG
  • Biogen, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Clearside Biomedical
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Iveric Bio
  • Kodiak Sciences
  • Kodiax Pharmaceuticals
  • Novartis AG
  • PulseSight Therapeutics
  • Regeneron Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
  • Samsung Bioepis.
  • Sandoz Inc.
  • Santen Pharmaceutical Co. Ltd.
Product Code: MRR-976C0ED91BDE

The Choroidal Neovascularization Market was valued at USD 6.88 billion in 2025 and is projected to grow to USD 7.36 billion in 2026, with a CAGR of 7.86%, reaching USD 11.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.88 billion
Estimated Year [2026] USD 7.36 billion
Forecast Year [2032] USD 11.69 billion
CAGR (%) 7.86%

A clear and comprehensive introduction to choroidal neovascularization that frames clinical characteristics, diagnostic improvements, and the evolving treatment landscape

Choroidal neovascularization (CNV) remains one of the most consequential complications affecting the choroid-retina interface, with implications for vision loss, long-term morbidity, and healthcare resource allocation. This introduction distills the clinical characteristics, diagnostic pathways, and contemporary standards of care that frame the therapeutic and commercial environment. Advances in multimodal imaging and earlier detection have reshaped patient journeys, enabling more timely interventions that alter disease trajectories and patient outcomes. These diagnostic gains, however, have increased the complexity of care coordination among ophthalmologists, retinal specialists, and ambulatory surgical centers.

Concurrently, treatment paradigms have evolved from focal therapies toward sustained biologic modulation of angiogenic pathways. Anti-VEGF agents have become central to clinical practice, while adjunctive approaches, including combination regimens and photodynamic therapy, persist in specific phenotypes or refractory cases. Payer policies and reimbursement coding have not always moved in lockstep with clinical innovation, creating variability in access and treatment continuity. As a result, stakeholders must navigate an intricate interplay between therapeutic efficacy, delivery logistics, and economic considerations when designing clinical programs and commercial strategies. This overview establishes the clinical and operational context necessary to evaluate subsequent sections on market shifts, segmentation insights, and strategic recommendations.

An interdisciplinary view of transformative scientific, clinical, and delivery-model shifts reshaping CNV treatment paradigms and stakeholder expectations

The landscape for CNV treatment is experiencing transformative shifts driven by scientific innovation, changing care delivery models, and a renewed focus on patient-centric outcomes. Biologic refinement and molecular engineering of anti-VEGF agents have extended durability and modified safety profiles, prompting clinicians to rethink dosing intervals and follow-up regimens. At the same time, real-world evidence and registry-driven insights are informing more nuanced therapy selection, especially for patients with complex lesion morphologies or those who demonstrate suboptimal response to first-line agents. These clinical dynamics are intersecting with operational changes: ambulatory surgical centers and ophthalmology clinics are increasingly equipped to deliver complex intravitreal therapies, while hospital systems continue to play a central role for higher-acuity presentations.

In parallel, payer scrutiny and value-based contracting conversations are influencing formulary positioning and access pathways. Manufacturers are responding with differentiated patient support programs and innovative distribution partnerships to reduce barriers to adherence. Technological advances in imaging and telemedicine have further enabled remote monitoring, which can reduce patient burden and improve adherence, but also require investment in interoperable systems and clinician training. Taken together, these shifts demand cross-functional strategies that align clinical differentiation, supply chain reliability, and stakeholder engagement to capitalize on therapeutic advances while safeguarding patient access and continuity of care.

A strategic analysis of how the 2025 United States tariff environment is reshaping supply chain resilience, manufacturing footprints, and commercial contracting for CNV therapies

The cumulative impact of United States tariff changes in 2025 is altering cost structures and supply chain dynamics that underpin CNV therapeutics and related medical devices. Tariff adjustments on imported biologic components, packaging materials, and specialized delivery devices have elevated sourcing costs for certain manufacturers, prompting them to reassess procurement strategies. As a result, some firms are accelerating initiatives to localize critical steps of biologic manufacturing or to diversify supplier bases across multiple geographies to mitigate exposure to trade policy volatility. This reconfiguration of supply chains can increase lead times and create short-term inventory imbalances that require proactive inventory and distribution planning.

Moreover, tariff-driven cost pressures are influencing the calculus around pricing, patient assistance programs, and contracting with payers. Health systems and distributors may face incremental logistical costs that translate into negotiations over reimbursement and formulary placement. In response, manufacturers are exploring near-term tactics such as hedging procurement contracts, modifying packaging to reduce tariffable components, and investing in regional fill-and-finish capacity. While these steps can stabilize supply, they also require capital allocation and regulatory alignment. Ultimately, the tariff environment is accelerating strategic decisions around manufacturing footprint, commercial contracting, and collaboration with end users to preserve timely access for patients while maintaining sustainable commercial models.

Deep segmentation insights linking treatment types, molecular classes, lesion and disease phenotypes, care settings, and distribution pathways to actionable clinical and commercial strategies

Segmentation analysis reveals how therapeutic choices, molecular classes, clinical presentations, lesion characteristics, lines of therapy, distribution channels, and end-user types collectively shape demand dynamics and care pathways. Treatment type remains a primary axis: anti-VEGF therapy dominates therapeutic decision-making, with molecule-level differentiation among agents such as aflibercept and ranibizumab that influence dosing cadence and patient follow-up. Bevacizumab retains relevance through cost-driven use in certain settings, while newer entrants with modified molecular structures aim to extend durability or alter safety profiles. Combination approaches that integrate photodynamic therapy with anti-VEGF agents are selectively employed for specific refractory or atypical presentations, and standalone photodynamic therapy, anchored by verteporfin, maintains a role in certain lesion subtypes.

Drug class segmentation highlights the operational and regulatory differences between fusion proteins and monoclonal antibodies; manufacturing complexity, cold-chain requirements, and patent landscapes differ across these classes and inform commercialization strategies. Disease-type distinctions between neovascular age-related macular degeneration and pathologic myopia dictate patient populations, natural history, and therapeutic responsiveness, requiring tailored clinical protocols. Lesion-type categories such as classic, mixed, and occult choroidal neovascularization present unique prognostic and treatment-response considerations that clinicians factor into initial therapy selection and monitoring frequency. Line-of-therapy segmentation underscores differences in goals between first-line interventions aimed at rapid disease control and second- or third-line approaches focused on refractory disease management. Distribution channel nuances between hospital and retail pharmacies affect dispensing workflows, reimbursement processes, and patient access points. Finally, end-user segmentation-spanning ambulatory surgical centers, hospitals, and ophthalmology clinics-captures the diversity of care settings where CNV treatments are delivered, each with distinct operational constraints, clinician expertise, and patient throughput considerations. Synthesizing these segmentation layers enables stakeholders to align clinical trial design, commercial messaging, and service delivery models to specific patient and provider contexts.

Regional strategic perspectives that reconcile clinical practice diversity, regulatory variation, and supply chain realities across major global healthcare regions for CNV

Regional dynamics exert a significant influence on clinical practice, regulatory pathways, and commercial models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, market evolution is shaped by advanced retinal care infrastructure and strong adoption of innovation in urban centers, while payer complexity and heterogeneous reimbursement policies create variable access pathways and necessitate tailored market access strategies. In contrast, Europe, Middle East & Africa encompasses diverse regulatory regimes and healthcare financing models, with some markets demonstrating rapid uptake of advanced biologics and others constrained by budget ceilings; these differences require nuanced country-level engagement and evidence generation to support reimbursement dossiers. Asia-Pacific presents a heterogeneous landscape where high-volume patient populations and growing specialist capacity coexist with differences in procurement practices, pricing sensitivity, and regulatory timelines; local manufacturing and regional partnerships can be decisive factors in commercial success.

Across these regions, differences in clinical practice patterns, imaging availability, and end-user capabilities influence treatment pathways and patient outcomes. Regional regulatory policies around biologics, biosimilars, and import controls interact with logistical realities to shape supply chain design and launch sequencing. Therefore, stakeholders must adopt regionally differentiated strategies that integrate health-economic evidence, local real-world data, and clinician engagement plans to ensure that therapeutic innovations translate into sustained clinical adoption and patient benefits.

Company-level competitive dynamics emphasizing molecular innovation, real-world evidence, patient support, and supply chain resilience as bases for differentiation in CNV

Key company-level dynamics center on innovation in molecule design, lifecycle management, and patient support infrastructure. Developers are advancing next-generation anti-VEGF agents that seek to extend durability, optimize safety, and differentiate via unique mechanisms or delivery formats. Strategic priorities include building robust real-world evidence programs to demonstrate comparative effectiveness, establishing comprehensive patient support and adherence services, and investing in manufacturing redundancy to reduce supply risk. Partnerships between innovator firms and specialty distributors or hospital systems are becoming more salient as companies seek to streamline product access and overcome logistical hurdles tied to complex biologic handling.

Competitive differentiation increasingly depends on the ability to demonstrate outcomes in varied lesion types and patient subsets, to engage payers through outcome-based arrangements, and to enable clinicians with practical tools for treatment decisions and imaging interpretation. Companies that successfully integrate clinical development with targeted health-economic data and that invest in scalable support programs for diverse care settings are best positioned to navigate reimbursement negotiations and to sustain adoption in the face of biosimilar or alternative therapeutic entrants. Observing these company behaviors provides a roadmap for supply chain investment, evidence-generation priorities, and commercial execution.

Actionable, prioritized recommendations for industry leaders to align evidence generation, manufacturing resilience, access programs, and payer engagement for CNV success

To translate the report's insights into operational advantage, industry leaders should prioritize a set of actionable initiatives that align clinical differentiation with commercial execution. First, concentrate evidence-generation efforts on head-to-head and real-world comparative studies that clarify therapeutic positioning across lesion subtypes and lines of therapy; such evidence will improve payer dialogues and clinician confidence. Second, invest in flexible manufacturing and regional fill-and-finish capabilities to reduce exposure to tariff-driven disruptions and to shorten lead times for critical supplies. Third, tailor access and patient support programs to the realities of different distribution channels and end users, ensuring that ambulatory surgical centers and ophthalmology clinics receive logistical and educational support to optimize adherence and outcomes.

Additionally, explore innovative contracting models with payers that tie reimbursement to measurable clinical outcomes, and deploy digital monitoring tools to support remote follow-up and adherence. Foster targeted partnerships with regional stakeholders to address regulatory and procurement heterogeneity, and design product launch sequencing that reflects regional readiness and infrastructure capacity. Finally, translate clinical differentiation into pragmatic clinician-facing resources-such as dosing algorithms and imaging interpretation guides-to reduce variation in care and to accelerate adoption in complex patient populations.

A rigorous, mixed-methods research methodology combining primary stakeholder interviews and systematic secondary evidence review with robust triangulation and quality controls

The research methodology underpinning this analysis integrates primary and secondary approaches to ensure robustness, validity, and practical relevance. Primary research involved semi-structured interviews with retina specialists, hospital pharmacy directors, clinic administrators, and payers to capture firsthand perspectives on treatment decision-making, operational constraints, and access challenges. Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory filings, clinical trial registries, and publicly available guidance from professional societies to map treatment paradigms and lesion-specific outcomes. Data triangulation combined qualitative insights with published clinical evidence to validate emergent themes and to surface discrepancies between clinical trial populations and real-world practice.

Quality control measures included cross-validation of interview findings across multiple stakeholder cohorts, transparent documentation of inclusion criteria for secondary sources, and sensitivity checks to assess the robustness of strategic conclusions. The methodology explicitly acknowledges limitations related to regional heterogeneity and evolving regulatory landscapes; where data gaps exist, the analysis highlights areas requiring further primary evidence generation. Ethical standards for primary research were maintained, with informed consent obtained for interviews and confidentiality assured for proprietary disclosures. This mixed-methods approach supports a balanced, evidence-informed perspective that is actionable for clinical, commercial, and policy stakeholders.

A conclusive synthesis of clinical innovation, operational resilience, and payer-aligned strategies to convert therapeutic advances in CNV into sustained patient and commercial outcomes

In conclusion, choroidal neovascularization remains a domain of rapid scientific and commercial evolution where clinical innovation, supply chain strategy, and payer engagement intersect to determine patient access and therapeutic success. Advances in anti-VEGF biology and adjunctive therapies are enabling more personalized treatment paradigms, but these opportunities must be matched by investments in evidence generation, manufacturing resilience, and targeted access programs. Tariff dynamics and regional regulatory complexity add layers of operational risk that companies can mitigate through diversified sourcing, regional partnerships, and proactive payer strategies.

Ultimately, organizations that synchronize clinical differentiation with pragmatic execution-through rigorous real-world studies, clinician-enabled adoption tools, and flexible commercial models-will achieve sustained adoption and deliver measurable patient benefit. The strategic recommendations and segmentation insights presented herein provide a framework to prioritize initiatives, align cross-functional teams, and convert clinical promise into enduring therapeutic impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Choroidal Neovascularization Market, by Treatment Type

  • 8.1. Anti-Vegf Therapy
    • 8.1.1. Aflibercept
    • 8.1.2. Bevacizumab
    • 8.1.3. Brolucizumab
    • 8.1.4. Conbercept
    • 8.1.5. Ranibizumab
  • 8.2. Combination Therapy
  • 8.3. Photodynamic Therapy

9. Choroidal Neovascularization Market, by Drug Class

  • 9.1. Fusion Proteins
  • 9.2. Monoclonal Antibodies

10. Choroidal Neovascularization Market, by Disease Type

  • 10.1. Neovascular Amd
  • 10.2. Pathologic Myopia

11. Choroidal Neovascularization Market, by Lesion Type

  • 11.1. Classic Cnv
  • 11.2. Mixed Cnv
  • 11.3. Occult Cnv

12. Choroidal Neovascularization Market, by Line Of Therapy

  • 12.1. First Line
  • 12.2. Second Line
  • 12.3. Third Line

13. Choroidal Neovascularization Market, by Distribution Channel

  • 13.1. Online
  • 13.2. Offline

14. Choroidal Neovascularization Market, by End User

  • 14.1. Ambulatory Surgical Centers
  • 14.2. Hospitals
  • 14.3. Ophthalmology Clinics

15. Choroidal Neovascularization Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Choroidal Neovascularization Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Choroidal Neovascularization Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Choroidal Neovascularization Market

19. China Choroidal Neovascularization Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Adverum Biotechnologies
  • 20.6. Apellis Pharmaceuticals, Inc.
  • 20.7. Astellas Pharma Inc.
  • 20.8. Bausch + Lomb Corporation
  • 20.9. Bausch Health
  • 20.10. Bayer AG
  • 20.11. Biogen, Inc.
  • 20.12. Chugai Pharmaceutical Co., Ltd.
  • 20.13. Clearside Biomedical
  • 20.14. F. Hoffmann-La Roche Ltd.
  • 20.15. Genentech, Inc.
  • 20.16. Iveric Bio
  • 20.17. Kodiak Sciences
  • 20.18. Kodiax Pharmaceuticals
  • 20.19. Novartis AG
  • 20.20. PulseSight Therapeutics
  • 20.21. Regeneron Pharmaceuticals Inc.
  • 20.22. Regeneron Pharmaceuticals Inc.
  • 20.23. Samsung Bioepis.
  • 20.24. Sandoz Inc.
  • 20.25. Santen Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)